Protalix BioTherapeutics, Inc. PLX

2.72 (0.03) (1.09%) as of 25 Sep
Market cap
$221.6M
P/E
11.3×
Insider Buys alert about insiders buying in the last 12 month

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Cash and Short Term Investments
30.98 34.83 44.56 22.18 38.99 38.55 17.79 37.81 51.16 63.28
Receivables
8.84 2.91 5.27 4.59 3.44 2.00 4.70 4.73 1.72 3.34
Inventory
25.73 21.24 19.05 16.80 17.95 13.08 8.16 8.57 7.83 5.25
Other current assets
1.13 1.10 1.06 1.31 1.29 2.10 1.83 1.88 1.93 2.17
Total current assets
66.67 60.08 69.93 44.88 61.67 55.72 32.48 52.98 62.65 71.87
Property, Plant, Equpment (Net)
4.88 4.59 4.97 4.55 4.96 4.85 5.27 6.39 7.68 8.70
Long Term Assets (Tax, Deferred)
2.52 2.86 3.09 — — — — — — —
Total non-current assets
15.67 13.34 14.50 10.91 12.00 12.21 12.91 8.15 9.56 10.38
Total Assets
82.35 73.42 84.43 55.79 73.67 67.93 45.39 61.13 72.21 82.25
Notes Payable
— — 20.25 — — 58.51 4.30 — 5.92 53.87
Accounts Payable
25.13 24.12 23.87 18.13 23.42 21.15 18.40 15.49 16.83 11.50
Current Revenue (Deferred)
— — — — — — — — — 0.84
Other current liabilities
— — — 13.18 8.55 5.39 16.34 9.87 9.31 8.33
Total current liabilities
26.52 25.62 45.53 32.43 33.18 86.47 40.18 25.35 22.75 66.21
Long Term Debt (Total)
— — — 28.19 27.89 4.47 50.96 47.97 46.27 19.34
Non-current Revenue (Deferred)
— — — — 11.79 1.72 16.98 33.03 25.02 —
Pension and Post-Retirement Liabilities
0.66 0.56 0.71 1.64 2.47 2.26 2.57 2.37 2.59 2.35
Non-current Liabilities (Other)
— — — 1.64 14.26 1.77 17.49 38.32 30.07 4.30
Total non-current liabilities
7.60 4.59 5.34 34.00 46.53 8.50 75.54 88.66 78.92 25.99
Total liabilities
34.12 30.21 50.87 66.43 79.70 94.97 115.71 114.01 101.67 92.20
Additional Paid In Capital
433.15 421.53 415.05 379.17 368.85 320.28 270.49 269.66 266.50 202.58
Common Stock (Net)
0.08 0.08 0.07 0.05 0.05 0.04 0.02 0.02 0.14 0.12
Retained Earnings
(385.00) (378.39) (381.55) (389.86) (374.93) (347.35) (340.83) (322.55) (296.10) (212.66)
Common Equity (Total)
48.23 43.21 33.57 (10.64) (6.04) (27.04) (70.32) (52.88) (29.46) (9.96)
Shareholders Equity (Total)
48.23 43.21 33.57 (10.64) (6.04) (27.04) (70.32) (52.88) (29.46) (9.96)
Shareholders Equity and Liabilities (Total)
82.35 73.42 84.43 55.79 73.67 67.93 45.39 61.13 72.21 82.25
Shares (Common)
80.43 75.85 72.95 53.79 45.56 34.77 14.84 14.84 14.37 12.41
Shareholders Equity (Tangible)
48.23 43.21 33.57 (10.64) (6.04) (27.04) (70.32) (52.88) (29.46) (9.96)
Net Debt
(30.97) (34.83) (44.56) 6.01 (11.10) (34.08) 33.17 10.16 (4.90) (43.94)
Total Debt
— — — 28.19 27.89 4.47 50.96 47.97 46.27 19.34

Fold the line items

In millions of $ except per-share values · columns are period end dates